Is the Chinese University of Hong Kong Hospital Suitable for Genetic Disease Patients for IVF? PGT and Genetic Counseling Analysis

Direct Answer: Is the Chinese University of Hong Kong Hospital Suitable for Genetic Disease Patients?

The Reproductive Medicine Centre of the Chinese University of Hong Kong Hospital has the capability to provide assisted reproductive treatment for genetic disease patients, but not all genetic disease patients are suitable for treatment at this centre. The prerequisites for suitability are: a clear diagnosis of the genetic disease, known causative gene, clear inheritance pattern, and compliance with relevant Hong Kong laws and regulations. The centre offers preimplantation genetic testing (PGT), including PGT-M for monogenic diseases and PGT-SR for chromosomal structural rearrangements, and is equipped with a genetic counseling clinic and genetic testing laboratory. For cases where the genetic cause is unknown, does not meet the indications for PGT technology, or involves legal or ethical controversies, treatment at this centre is not suitable.

Doctor's Perspective: Core Considerations for Genetic Disease Patients Choosing a Reproductive Centre

From a clinical reproductive medicine perspective, when choosing a reproductive centre, genetic disease patients need to focus on the following core elements:

• Genetic Counseling Capability: Whether there is a multidisciplinary team composed of medical geneticists and reproductive doctors who can accurately assess the recurrence risk of the genetic disease and formulate a personalized PGT plan.
• PGT Technology Platform: Whether it possesses both PGT-M and PGT-SR technical capabilities, and whether the laboratory has mature platforms such as single-cell amplification, NGS sequencing, and SNP arrays.
• Genetic Testing Support: Whether the pathogenic gene identification for the proband and parents can be completed within the centre or in a partner laboratory, avoiding cycle delays and sample management issues caused by sending tests out.
• Legal and Ethical Compliance: Whether local laws permit embryo selection for the genetic disease in question. For example, Hong Kong has clear regulations on the indications for PGT, and some non-fatal or late-onset genetic diseases may not be included.
• Embryology Laboratory Quality Control: PGT requires high standards for embryo biopsy and cryopreservation. The laboratory's quality control system directly affects the survival rate of embryos after biopsy and the success rate of transfer.

The Chinese University of Hong Kong Hospital meets international standards in the above four dimensions. Its Reproductive Medicine Centre works closely with the Department of Obstetrics and Gynaecology and the Department of Chemical Pathology of the Chinese University of Hong Kong, forming a full-chain service from genetic counseling to genetic testing and then to PGT.

Why Genetic Disease Patients Need Specialized Assisted Reproductive Evaluation

The assisted reproductive treatment path for genetic disease patients is fundamentally different from that for ordinary infertile couples. The core issue is not "whether pregnancy can be achieved," but "how to avoid passing the genetic disease to offspring." Conventional in vitro fertilization (IVF) cannot solve the problem of disease transmission; it must rely on PGT technology for genetic screening before embryo implantation. This means:

• A clear diagnosis of the causative gene in the proband (the patient themselves or an affected child) must first be completed; this is a prerequisite for PGT.
• A family genetic pedigree needs to be constructed to clarify the inheritance pattern (autosomal dominant/recessive, X-linked, mitochondrial, etc.) in order to design the PGT testing plan.
• It is necessary to assess whether there is genetic heterogeneity or de novo mutations that can be intervened upon; some patients may require additional linkage analysis or haplotype construction.
• It is necessary to confirm whether the genetic disease falls within the indications for PGT; not all genetic diseases are suitable for embryo screening.

The genetic counseling clinic at the Chinese University of Hong Kong Hospital systematically completes the above assessments to determine whether the patient is truly suitable to enter a PGT cycle.

Actual Process: IVF Path for Genetic Disease Patients at the Chinese University of Hong Kong Hospital

The assisted reproductive process for genetic disease patients at this centre is divided into the following stages:

Timeline: How Long from Initial Consultation to Transfer

The IVF cycle for genetic disease patients is usually longer than a standard IVF cycle, mainly because the preliminary genetic counseling and genetic testing require additional time:

• Genetic Counseling and Genetic Testing: 4-8 weeks, depending on whether new genetic tests or family validation are needed.
• IVF Cycle (stimulation to embryo biopsy): 4-6 weeks.
• PGT Testing Cycle: 2-3 weeks.
• Preparation for Transfer Cycle: 4-6 weeks (adjusted according to endometrial condition).

The entire process from initial consultation to completed transfer usually takes 4-6 months. If the patient has already completed pathogenic gene testing and has a clear report, the time can be shortened to 3-4 months.

Details Most Easily Overlooked

In clinical work, the following details are often overlooked by genetic disease patients but directly affect the success of treatment:

• Timeliness of Genetic Disease Diagnosis: If genetic test reports are more than 2 years old, due to updates in testing technology or database improvements, re-verification or supplementary testing may be required.
• Completeness of Family History: Information on illness, causes of death, and miscarriage history of first- to third-degree relatives must be provided completely; otherwise, it may affect the determination of the inheritance pattern.
• Limitations of PGT Testing: PGT-M cannot detect all known pathogenic genes, and its sensitivity is limited, especially for mosaicism, de novo mutations, or complex structural rearrangements. Patients need to be informed in advance and sign informed consent.
• Risk of No Usable Embryos: For autosomal dominant diseases, theoretically 50% of embryos may carry the pathogenic gene. For carriers of balanced chromosomal translocations, the proportion of normal or balanced embryos is usually only 20%-30%. Patients need to be mentally and financially prepared.
• Hong Kong Legal Restrictions on PGT: Hong Kong's Human Reproductive Technology Ordinance has clear regulations on the indications for PGT. Embryo screening may not be permitted for certain genetic diseases (e.g., late-onset neurodegenerative diseases).

Common Pitfalls

Based on feedback from past cases, the following issues are prone to occur during the treatment of genetic disease patients at the Chinese University of Hong Kong Hospital:

• Non-standard Genetic Test Reports: Some patients provide genetic test reports from other hospitals that lack pathogenicity ratings or have not completed family validation, requiring re-testing and leading to cycle delays.
• Skipping the Genetic Counseling Step: Some patients mistakenly believe they can directly enter an IVF cycle without booking a genetic counseling appointment in advance, resulting in a wait for a genetic counseling slot after the initial visit.
• Overly High Expectations of PGT Success Rate: After PGT screening, usually only 30%-50% of embryos are available for transfer. For women with diminished ovarian reserve, there may be no embryos available for transfer.
• Incomplete Legal Documentation: Hong Kong has strict requirements for legal consent forms related to PGT, including genetic counseling informed consent, PGT testing consent, and embryo disposal consent. These need to be understood and prepared in advance.
• Neglecting Male Partner Evaluation: For some genetic diseases (e.g., autosomal dominant), the male partner may also carry the pathogenic gene. The male partner requires independent genetic counseling and testing; the evaluation should not focus solely on the female.

Frequently Asked Questions

Below are the most common questions asked by genetic disease patients in the clinic:

• Q: I have polycystic kidney disease (autosomal dominant). Can I undergo PGT?
  A: Yes. However, you first need to complete testing for the causative gene (PKD1/PKD2) and confirm the genotypes of other affected family members. PGT-M can effectively screen out embryos that do not carry the pathogenic gene.
• Q: My husband and I are both thalassemia carriers. Can PGT guarantee that our child will not have the disease?
  A: For alpha or beta thalassemia, if the causative genes of both partners are clear, PGT-M can screen out embryos carrying 0 or 1 pathogenic gene (carriers are not affected), but it cannot completely avoid all types of thalassemia.
• Q: For a carrier of a balanced chromosomal translocation, what is the success rate of PGT-SR?
  A: After PGT-SR screening, the proportion of normal or balanced embryos for balanced translocation carriers is approximately 20%-40%, depending on the type of translocation and the breakpoint location.
• Q: How much does PGT cost at the Chinese University of Hong Kong Hospital?
  A: The testing cost for PGT-M or PGT-SR is usually between HKD 50,000 and 80,000. Including the IVF cycle cost, the total cost is approximately HKD 120,000 to 180,000. The specific cost varies depending on the testing plan and medication used.
• Q: I have a genetic disease, but my husband does not. Do I still need PGT?
  A: If it is an autosomal dominant disease, even if the husband is not affected, he still needs genetic testing to confirm whether he is a carrier. If it is an X-linked disease, the evaluation depends on the specific inheritance pattern.

Observations from Practitioners

As a reproductive doctor who has encountered many genetic disease patients during their treatment, here are a few observations for reference:

First, before deciding to undergo IVF, genetic disease patients have often been through a long diagnostic process. Some patients have carried reports of pathogenic genes for years but have never had systematic genetic counseling. These patients need to have their complete genetic information re-evaluated; old reports cannot be used directly.

Second, although PGT technology is advanced, it is not suitable for all genetic diseases. For some polygenic diseases (e.g., diabetes, hypertension) or diseases primarily influenced by environmental factors, PGT is not applicable. Some patients have the misconception that PGT can "screen for all diseases," which requires careful explanation by the doctor.

Third, the Chinese University of Hong Kong Hospital has an advantage in multidisciplinary collaboration. Genetic counseling, PGT testing, and obstetric follow-up can be completed in an integrated manner, reducing the need for patients to travel between different institutions. However, patients need to allocate sufficient time to complete the entire cycle in Hong Kong, especially the genetic testing phase, which may require multiple trips.

Fourth, psychological support is particularly important during the treatment of genetic disease patients. Some patients experience significant psychological stress due to the stigma associated with genetic diseases or excessive anxiety about the health of their offspring. It is recommended to undergo psychological evaluation and necessary intervention before treatment.

Risk Reminders

Before choosing the Chinese University of Hong Kong Hospital for assisted reproductive treatment, genetic disease patients need to fully understand the following risks:

• PGT testing has technical limitations and cannot detect all types of genetic diseases 100%. There is a very low risk of misdiagnosis or missed diagnosis.
• Approximately 1%-2% of embryos may stop developing due to the biopsy procedure, leading to a reduction in the number of usable embryos.
• After PGT screening, some embryos may still have unclear diagnoses due to chromosomal mosaicism or other complex reasons, requiring additional testing or being discarded.
• Hong Kong law has strict restrictions on the types and number of embryos that can be screened. PGT may not be permitted for certain genetic diseases.
• The treatment cycle is long (4-6 months) and requires multiple trips to Hong Kong. The time cost and travel expenses need to be planned in advance.

It is recommended that patients communicate fully with their reproductive doctor and genetic counselor before starting treatment to clarify the suitability of their specific genetic disease, the success rate, and potential risks, in order to make a rational decision.